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Abstract.  Fibronectin molecules are dimers composed 
of subunits whose primary structures may differ. This 
is due to alternative splicing in at least two regions 
(ED and IIICS) of the pre-mRNA. 
Using two monoclonal antibodies specific for two 
different epitopes of domain 5  (high affinity for hepa- 
rin), we have quantitatively analyzed the expression of 
the IIICS sequence in human fibronectins from differ- 
ent sources.  The results demonstrated that the percent- 
age of fibronectin subunits containing the IIICS is 
higher in fibronectins from tumor-derived or simian 
virus 40-transformed human cells than in fibronectins 
from human plasma or normal human fibroblasts. 
Furthermore, we observed that 45-65 % of fibronec- 
tin subunits from transformed cells or normal em- 
bryonic fibroblasts are sialylated on the heparin- 
binding domain 5,  whereas this occurs in only 
24-28%  of fibronectin subunits from normal adult 
fibroblasts.  On the contrary, no sialylation was ob- 
served on domain 5  in fibronectin from human 
plasma. 
F 
IBRONECTINS (FNs) ~ are high molecular weight ad- 
hesive glycoproteins present in soluble form in plas- 
ma and other body fluids and in insoluble form in the 
extracellular matrices and basement membranes. FN mole- 
cules act as bridges between the cell surface and extracellular 
material. In fact, the FN molecules contain a cell-binding 
site and binding sites for collagen, heparin, ganglioside, and 
fibrin. Due to their multiple interactions FNs play an impor- 
tant  role  in  diverse  biological  phenomena  including cell 
adhesion, cell migration, hemostasis and thrombosis, wound 
healing, and the ability to induce a more normal phenotype 
in transformed cells (for reviews on distribution, structure, 
and biological functions see references 1, 3, 4,  13, and 16). 
Recently it has been demonstrated that the FN polymor- 
phism may be due to alternative splicing schemes since many 
different mRNAs may originate from the primary transcript 
of a single gene (5, 7-10, 17, 18, 22) localized on chromosome 
two (6, 27). 
Here,  using the domain-specific monoclonal antibodies 
IST-7 and IST-2 we have studied the presence of the IIICS se- 
quence in FN from plasma and from the conditioned media 
of normal and tumor-derived human cells. 
Materials and Methods 
Cell Lines and Monoclonal Antibodies 
Cultured normal human fibroblast cell lines (LZ, from adult human skin; 
GM-3651-C,  from adult human skin; GM-5386,  from embryonic human 
1. Abbreviations used in this paper: FN, fibronectin; RIA, radioimmunoas- 
say;  SV-40, simian virus 40. 
skin; WI-38, from embryonic human lung) and transformed cell lines (HT- 
1080, from a human fbrosarcoma; RD, from an embryonic human rhab- 
domyosarcoma; IgR3, from a human melanoma; and WI-38VA13, simian vi- 
rus 40 lSV-40]-transformed WI-38 cells) were grown in Eagle's minimum 
essential medium supplemented with 10% fetal calf serum (Flow Laborato- 
ries, Irvine,  Scotland) that had been depleted of bovine FN by passage 
through a large capacity gelatin-Sepharose column. 
Monoclonal antibodies to human plasma FN were prepared as previously 
described (25).  Partial characterization of the monoclonal antibody IST-2 
has been previously reported (19, 21). The IST-2 monoclonal antibody is 
available  from Sera Lab (Crawley Down, England). 
Purification  and Thermolysin  Digestion of  FN 
FNs were purified from human plasma and from the conditioned media of 
the various cell lines as previously reported (26). Thermolysin digestion of 
FNs was performed as described by Sekiguchi and Hakomori (20).  SDS 
PAGE and immunoblouing were carried out as described (11, 23). 
Purification  of Domain 5 and 
Neuraminidase Treatment 
Domain 5 was purified as previously described using a hydroxyapatite chro- 
matography column (28).  Neuraminidase (Neurarninidase-Test, Behring- 
werke, Marburg, FRG) treatment of purifed domain 5 was carried out by 
incubating the polypeptides (0.2 mg/ml final concentration) in 0.05 M so- 
dium acetate buffer, 0.154 M NaC1, 9 mM CaCI2 (pH 5.5) with 0.5 U/ml of 
neuraminidase for 1 h at 37°C. 
Affinity Chromatography  on Heparin-Sepharose 
5 mg of FN thermolysin digest (5 I.tg of thermolysin/mg of fibronectin in 
25 mM Tris-HCl, pH 7.6, containing 0.5 mM EDTA, 50 mM NaCI) were 
loaded  on  a  heparin-Sepharose (Pharmacia,  Uppsala,  Sweden)  affinity 
chromatography column (1.6 x  4 cm) previously equilibrated in the above- 
mentioned buffer. 
After washing with 40 ml of the same buffer (heparin-unbound fraction), 
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Figure 1. Proposed model for thermolysin fragmentation of the a- and [~-subunits  of FN. Fragmentation pathways after limited proteolysis 
with thermolysin of FN subunit a  (containing the IIICS sequence) and 13 (without the IIICS sequence) are schematically presented based 
on previous reports (19-21,  28),  and the results reported are here. White arrows indicate the sites where the two monoclonal antibodies 
IST-2 and IST-7 react. Arrowheads indicate the thermolysin cleavage sites. The figure also indicates the internal homologies (I-III) (15). 
The Journal of Cell Biology, Volume 103, 1986  1672 Figure 2. (A) 4-18 % SDS PAGE gradients of FNs from different sources digested for 4 h at 22°C by thermolysin (50 gg/mg of FN). Lanes: 
1, human plasma FN; 2, FN from conditioned medium of GM-5386 normal human embryonic fibroblasts; 3, FN from conditioned medium 
of HT-1080 human fibrosarcoma cells; 4, FN from conditioned medium of WI-38VAI3 cells SV40-transformed human WI-38 lung fibroblasts; 
5, FN from conditioned medium of IgR3 human melanoma cells. The values on the left are the molecular masses (in kD) of standards. 
(B)  Immunoblot  analysis  of a  4-18%  SDS  PAGE gradient  identical  to  that  shown  in A,  using the  monoclonal  antibody  IST-2.  This 
monoclonal recognizes domains 4+51]  (115 kD), 4+5¢t  (145 kD),  513 (38 kD), and domain 5¢t in the sialylated and nonsialylated forms 
(33 and 29 kD). For FN domains nomenclature and structure see Fig. 1. (C) Immunoblot analysis of a 4-18 % SDS PAGE gradient identical 
to that shown in A, using the monoclonal antibody IST-7. This antibody recognizes a  155-kD fragment (domains 4+513), a 38-kD fragment 
(domain 513), and a  12-kD fragment (domain 5¢t2). The 12-kD fragment is barely visible probably because this low molecular mass frag- 
ment interacts weakly with the nitrocellulose sheets. In milder digestion conditions this antibody also recognizes a 175-kD fragment (domain 
4+513+6).  For FN domains nomenclature and structure  see Fig.  1. 
bound polypeptides were eluted using 25 mM Tris-HCl, pH 7.6 buffer con- 
taining 0.5 mM EDTA, 0.7 M NaCI. All operations were carried out at a 
flow rate of 20 ml/h.  1.5-ml fractions were collected. 
Radioimmunoassay (RIA  ) 
The solid-phase double-antibody RIA method was used for the quantitative 
competition binding assay (24). Competition reactions were carded out in 
PBS containing 1 mg/ml of  bovine serum albumin (BSA), 5 U/ml aprotinin, 
and  0.2  mM  phenylmethylsulfonyl  fluoride  (Sigma  Chemical  Co.,  St. 
Louis,  MO). 
The heparin-bound  and  unbound  FN fractions  (obtained as described 
above) were, after dialysis, diluted with PBS m identical volumes (10 ml), 
and BSA and apmtinin were added to give a final concentration of 1% and 
10 U/ml, respectively. The competition binding assay was carried  out on 
these fractions using the monoclonal  antibody IST-7. 
Various dilutions  of the heparin-bound  and heparin-unbound  fractions 
were incubated with a monoclonal  antibody  (at a dilution that had given 
50%  maximum binding in titration  experiments)  for  1 h at 37°C. 
The mixtures  were then  transferred  into the wells of polyvinyl  plates 
(Cooke Labs, Alexandria, VA) previously coated with purified FN, and in- 
cubated for 2 h. Then the mixture was removed and the wells were washed 
with PBS. The amount of antibody bound was detected by adding specific 
125I-labeled rabbit anti-mouse Ig and incubating for 2 h at room tempera- 
ture.  The dilutions  of heparin-bound  and heparin-unbound  fractions  that 
could give a 50% inhibition were used to calculate the ratio between the 
Ix- and  [i-subunits. 
Results 
Characterization of  Monoclonal Antibodies 
IST-2 and IST-7 
The  monoclonal  antibody  IST-2  has  previously  been  par- 
tially  characterized  (19,  21).  It  reacts  with  the  heparin- 
binding domain 5 which is comprised of the COOH-terminal 
four type III homology repeats (21) (see Fig.  1). This domain 
is present in the different FN molecules with differences  in 
the primary structure since different portions of a 120 amino 
acid segment (IIICS) may be inserted between  the last two 
type HI homology repeats; this is due to alternative patterns 
of RNA  splicing  (7-10,  17). 
After  thermolysin  digestion  of plasma  FN,  IST-2  reacts 
with  two  fragments  of 38  and 29  kD  which  represent  the 
heparin-binding domain 5  (19, 21, 28).  Both the 38 and 29- 
kI) fragments are extremely resistant to thermolysin. Diges- 
tion  of the  purified  38-kD  fragment by  50  gg  of thermo- 
lysin/mg  of 38-kD  fragment  did  not  generate  any  29-kD 
fragment or other degradation peptides.  Identical resistance 
to thermolysin was shown by the 29-kD fragment.  Purifica- 
tion (28) and primary structure studies (14; and Pande,  H., 
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Figure 4. Densitometric scanning of immunoblots, stained using the 
monoclonal antibody IST-2, of thermolysin digested FNs. 38-, 33-, 
and 29-kD peaks represent domain 513, sialylated domain 50t=, and 
domain 50tj respectively. 
Figure 3.  4-18% SDS  PAGE gradients of the  purified heparin- 
binding domains 5fi (38 kD) and 5a] (29 and 33 kD) from a ther- 
molysin digest of FN from the tissue culture medium of WI-38 nor- 
mal human fibroblasts. Lanes 1 and 3, purified domains 513 and 
5ctt. Lanes 2 and 4, purified domains 5fl and 5~t~ treated with 0.5 
U/ml of neuraminidase (Neu.) at 37°C for 1 h and 3 h, respectively 
(see Materials and Methods). The values on the left and on the right 
are the molecular masses (in kD). 
J.  Calaycay, T. Lee, K. Legesse, J.  E.  Shively, A.  Siri, L. 
Borsi, and L. Zardi, manuscript submitted for publication) 
of these two fragments demonstrated that the 38-kD frag- 
ment (domain 513) contains the four repeats of type HI ho- 
mology with the deletion of the entire 120 amino acid IIICS 
sequence, whereas the 29-kD fragment (domain 5(x0 con- 
tains the first three repeats of type III homology plus a small 
portion of the connecting segment (IIICS) (see Fig. 1). These 
data indicate that the monoclonal antibody IST-2 reacts with 
an antigenic determinant present on the first three type III ho- 
mology repeats (Fig.  1) and that the presence of the IIICS 
sequence introduces into the FN molecule a site that is very 
sensitive to the proteolytic enzyme thermolysin. 
The monoclonal antibody IST-7 reacts with the 38-kD (do- 
main 513) but not the 29-kD  fragment (domain 5a~)  (Fig. 
2). It also reacts with a smaller fragment of ~12 kD (domain 
5a2) (Fig. 2),  which represents the last type III homology 
repeat, as also confirmed by the NH2-terminal amino acid 
sequence of the purified fragment (data not shown). This 12- 
kD  fragment (domain 5a2) does not have heparin-binding 
activity (data not shown), which is the characteristic of do- 
mains 5a~  and 513. 
Domain 5 May Be Sialylated 
The monoclonal antibody IST-2, which reacts with the 38- 
and 29-kD fragments of plasma  FN,  also reacts  with FN 
from the spent media of different human cell lines with an 
extra band having a molecular mass of '~33 kD (see Fig. 2). 
This band does not react with the monoclonal IST-7, indicat- 
ing that this fragment lacks the last type III homology repeat. 
Furthermore, this  fragment shows  as  great an affinity for 
heparin as do the 29- and 38-kD fragments (data not shown). 
All three of these fragments were purified and treated with 
different amounts of neuraminidase (Fig. 3). The 38- and 29- 
kD fragments did not show any change in molecular mass, 
whereas that of the 33-kD fragment decreased to '~30 kD. 
The fact that neuraminidase treatment does not reduce the 
33-kD fragment exactly to 29 kD is very likely due to either 
incomplete desialylation or the presence of other carbohy- 
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Figure  5. Schematic outline of FN ct- and I~-subunit determination. Hatched areas indicate heparin-binding fragments; white arrows indicate 
the reaction sites of  the monoclonal antibodies IST-2  and IST-7, respectively. Arrowheads indicate thermolysin cleavage sites. The expression 
of the IIICS sequence (subunit ~t) introduces into the FN molecule a new cleavage site and after thermolysin digestion the fragment contain- 
ing the immunologic determinant recognized by IST-7 is separated from the heparin-binding domain and it elutes in the heparin-unbound 
fractions. On the contrary, when the IIICS sequence is deleted (13-subuni0 thermolysin cannot separate the determinant recognized by IST-7 
from the heparin-binding sequence. Using the RIA described in Materials and Methods, the determinant recognized by the monoclonal 
IST-7 was measured in the heparin-bound and heparin-unbound fractions. The ratio between the amount of determinant present in the 
heparin-unbound and heparin-bound fractions corresponds to the ratio between the ct- and 13-subunits. 
drates.  Neuraminidase  treatment  also  induced  a  drastic 
change in the isoelectric point of the 33-kD fragment (from 
8.3  to 9.3),  whereas  it did not induce any change in the 
charge of the other two fragments. These data indicate that 
the 33-kD fragment represents a glycosylated form of the 29- 
kD fragment (domain 5ai). 
Determination of the Expression of the IIICS 
Sequence in FN  from Different Sources 
To estimate the presence of the IIICS sequence in FN from 
different sources we used two different approaches, using the 
monoclonal antibodies IST-2 and IST-7, and the different sen- 
sibilities of the two FN subunits to thermolysin: (a) Since the 
38-kD fragment originates from the FN subunit in which the 
IIICS sequence is completely deleted and the 29- and 33-kD 
fragments originate from the FN subunit in which the mCS 
sequence is at least partially expressed (14; and Pande, H., 
J.  Calaycay, T.  Lee, K. Legesse, J.  E. Shively, A.  Siri, L. 
Borsi, and L. Zardi, manuscript submitted for publication), 
the ratio between the 38-kD fragment and the 33  +  29 kD 
fragments represents the ratio between the 13- and ct-subunits 
in the different FNs. To estimate the relative amount of each 
of these fragments we performed a densitometric scanning 
of immunoblots stained using the monoclonal antibody IST-2 
(Fig. 4). The percentage of the area of each peak is reported 
in Table I. (b) The second procedure involved the use of the 
monoclonal antibody IST-7  (specific for domains  513  and 
5(t2) and is based on the observation that when the IIICS 
sequence is deleted, the proteolytic enzyme thermolysin can- 
not separate the determinant recognized by IST-7 from the se- 
quence with heparin affinity. On the contrary, the expression 
of the IIICS sequence introduces into the FN molecule a site 
extremely sensitive to thermolysin and after digestion the 
fragment containing the  determinant recognized by IST-7 
cannot bind heparin (see Fig. 5). 
Fig. 6 shows competition RIA experiments for the binding 
of the monoclonal antibody IST-7 using the heparin-bound 
and heparin-unbound fractions of the thermolysin digests of 
different FNs. The data are summarized in Table I (for the 
procedure see Materials and Methods). 
The results obtained with the two procedures were nearly 
identical (Table I) and demonstrated that the percentage of 
the a-subunit (containing the IIICS sequence) is higher in 
virus-transformed or tumor-derived cells with respect to nor- 
mal fibroblasts or plasma. 
Furthermore, the percentage of the glycosylated domain 
5~t seems to be higher in FNs  from embryonic or trans- 
formed cells with respect to normal cells (Table I). 
Discussion 
In  this  work we  provide evidence that  tumor-derived or 
transformed  human  cells  release  into  the  culture  media 
different FN variants than do normal cells. 
It has previously been demonstrated that the FN polymor- 
phism is due to alternative splicing schemes in at least two 
regions (IIICS and ED) of the pre-mRNA (7-10, 17, 18, 22). 
Previous studies (8, 9) have suggested that the ED segment 
seems to be absent in the hepatocyte mRNAs, which are the 
source of plasma FN, and it is probable that the inclusion of 
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Figure 6.  Competitive inhibition 
of  binding of  the monoclonal anti- 
body  IST-7  to  normal  human 
fibroblast FN (GM-3651-C). Ali- 
quots of the monoclonal antibody 
IST-7 were mixed with different 
dilutions  of  the  heparin-bound 
(O) and heparin-unbound (e) pep- 
tides from thermolysin digests of 
various  FNs.  For the procedure 
see Materials  and  Methods.  (A) 
Human plasma FN; (B) FN from 
spent  medium  of normal  fibro- 
blasts; (C) FN from spent medi- 
um  of melanoma  cells  (IgR3); 
and (D) FN from spent medium 
of SV-40-transformed human  fi- 
broblasts (WI-38 VA13). 
the ED sequence is characteristic of cellular FN.  Recently, 
Schwarzbauer et al.  (18),  using  a  rabbit antiserum to the 
IIICS sequence, have demonstrated that the great majority of 
the FN molecules from a rat cell line contains the IIICS se- 
quence while on the contrary, a  sizeable proportion of rat 
plasma FN was lacking the sequence.  Furthermore,  it has 
been recently demonstrated that at least part of the IIICS se- 
quence is present in the ct-subunit of human plasma FN (2, 
14;  and Pande,  H., J.  Calaycay, T.  Lee, K.  Legesse, J.  E. 
Shively, A. Siri, L. Borsi, and L. Zardi, manuscript submit- 
ted for publication). 
Here we show that the expression of the IIICS sequence 
introduces into the FN molecule a region that is susceptible 
to thermolysin cleavage. This agrees with previous indica- 
tions of a different susceptibility to proteolytic enzymes in 
the COOH-terminal region of the two FN subunits (2, 11, 15, 
20, 23, 24, 26). Thus, thermolysin digestion of subunits con- 
taining the IIICS sequence produces fragments different with 
respect to those originating from FN molecules in which the 
IIICS sequence is deleted. Using two monoclonal antibodies 
(IST-2 and IST-7), the different susceptibilities to thermoly- 
sin of the two FN subunits, and the affinity for heparin of the 
different  FN  thermolysin  fragments,  we  have  set  up  two 
procedures for the quantitative determination of the expres- 
sion of the IIICS sequence in  FN  from different sources. 
However, five splicing variants within the I/ICS have been 
demonstrated in human FN (10). In fact, the 120 amino acids 
of the IIICS segment may be present or deleted, or portions 
of 95,  89,  or 64 amino acids may be expressed in the FN 
molecules (10). The two procedures described here can only 
discriminate  whether  the  HICS  sequence  is  completely 
deleted or at least partially expressed. 
Using these procedures we have observed that: (a) the per- 
centage of molecules containing  at least part of the IIICS 
sequence varies depending  on the FN source;  and (b) ex- 
pression of the IIICS sequence is higher in FN from tumor- 
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Different Sources 
From RIA 
From densitomet- 
tic scanning of 
immunoblots 
Source of FN  a  I~  ~t*  13 
Plasma  60  40  60  (0)  40 
Normal human embryonic  75  25  78  (45)  22 
fibroblast (GM5386) 
Normal human embryonic  75  25  78  (43)  22 
fibroblast (WI-38) 
Normal human adult  72  28  73  (28)  27 
fibroblast (GM365 I-C) 
Normal human adult  nd  nd  76  (24)  24 
fibroblast (LZ) 
Fibrosarcoma  90  10  88  (62)  12 
(HT-1080) 
Rhabdomyosarcoma  100  0  100  (67)  0 
(RD) 
Melanoma  80  20  80  (55)  20 
(IgR3) 
SV-40-transformed human  100  0  100  (65)  0 
fibroblast (WI-38/VA13) 
Percentage of a- and 13-FN subunits as estimated using the RIA method with 
the IST-7 monoclonal antibody and by densitometric scanning of immunoblots 
with the IST-2 monoclonal antibody.  FN was from plasma or from the spent 
media of the different cell lines. 
* The percentages of subunits in which domain 5 is sialylated are indicated in 
parentheses,  nd,  not determined. 
derived and SV-40-transformed cells with respect to normal 
fibroblasts and plasma.  These results suggest a specifically 
programmed splicing mechanism in different cell types and 
that in transformed or tumor-derived cells these mechanisms 
are altered. Recently Matsuura and Hakomori, using mono- 
clonal antibodies, found a domain that is present in FNs from 
tumors and fetal tissues but absent in those from adult tissues 
and plasma (12). We can exclude that the monoclonal anti- 
bodies prepared by Matsuura and Hakomori (12) recognize 
some antigenic determinant on the IIICS domain since this 
is also present in plasma FN. 
Furthermore, we demonstrated that the FN domain 5a~ 
(which contains part of the HICS sequence) is sialylated in 
some FN molecules from spent media of  culture cells but not 
in plasma FN. The percentage of the sialylated domain 5cq 
in FN from the spent media of embryonic fibroblasts is about 
twice that in FN from the spent media of adult fibroblasts. 
The percentage of sialylated domain 5ct~ is even higher in 
FN from the spent media of transformed cells. We did not 
observe any sialylation of domain 513 (from which the IIICS 
sequence is deleted). 
Future research should be directed towards establishing 
the  biological consequences of these  structural  modifica- 
tions. 
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